Table 3.
Participant Characteristics at baseline [53]
| Control Group (14) | Intervention Group (16) | |
|---|---|---|
| Age (Years), Mean (SD) | 45 (9.4) | 41.5 (8.2) |
| Female/Male | 7/7 | 8/8 |
| Height (cm), Mean (SD) | 173 (8.7) | 176 (9.5) |
| Weight (kg), Mean (SD) | 76 (10.7) | 80 (15.8) |
| BMI, MEAN (SD) | 25.4 (3.3) | 25.9 (5.1) |
| Side of injury (L/R) | 7/7 | 10/6 |
| Duration of Symptoms (months) | 14 (16.2) | 10 (7.2) |
| Flouroquinolone antibiotics (Y/N) | 0/14 | 0/16 |
| Corticosteroids (Y/N) | 0/14 | 2/14 |
| Anti-inflammatory medication (Y/N) | 4/10 | 6/10 |
| Statin medication (Y/N) | 0/14 | 0/16 |
| Diabetes medication (Y/N) | 0/14 | 0/16 |
| Allopurinol medication (Y/N) | 0/14 | 0/16 |
| Aromatrose inhibitors | 0/14 | 0/16 |
| Physical Activity Levels (active/inactive) | 14/0 | 12/4 |
| International Physical Activity Questionnaire (High/Moderate/Low) | 7/7/0 | 6/9/1 |
| Presence of comorbidities (Y/N) | 1/13 | 1/15 |
| Inflammatory or rheumatoid arthritis (Y/N) | 0/14 | 0/16 |
| Psoriasis (Y/N) | 1/13 | 1/15 |
| Inflammatory bowel or eye disease (Y/N) | 0/14 | 0/16 |
| Ankylosing spondylitis (Y/N) | 0/14 | 0/16 |
| Gout (Y/N) | 0/14 | 0/16 |
| Diabetes 1 or 2/ impaired glucose sensitivity (N) | 0/14 | 0/16 |
| Hypertension or cardiac disease (Y/N) | 1/13 | 1/15 |
| Hypertriglyceridemia/ high cholesterol (Y/N) | 2/12 | 0/16 |
| Familial hypercholesterolemia (Y/N) | 5/9 | 8/8 |
| Collagen disorders (Y/N) | 0/14 | 0/16 |
| Fibromyalgia (Y/N) | 0/14 | 0/16 |
| Imaging (N/MRI/US) | 11/2/1 | 16/0/0 |
| Prior History of Tendinopathy (N/Achilles/Patellar) | 9/4/1 | 10/5/1 |